Lycia Therapeutics
Biotechnology ResearchCalifornia, United States11-50 Employees
At Lycia, we aim to eliminate the source of disease using the power of extracellular protein degradation. Our novel LYTAC therapeutics are designed to bind and remove disease-causing extracellular proteins by directing them into the cell for degradation via the lysosome. Focused initially on autoimmune and inflammatory diseases, our platform addresses gaps in targeting proteins outside the cell, offering new hope to patients who urgently need better options.
1-888-653-2347 
support@leadiq.com 
